Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

BACKGROUND: Trastuzumab-based therapy after diagnosis of brain metastases (BM) may improve survival due to prolonged systemic disease control. We investigated whether lapatinib may yield additional survival benefit. METHODS: Eighty patients with BM from HER2-positive breast cancer were identified. K...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bartsch, R, Berghoff, A, Pluschnig, U, Bago-Horvath, Z, Dubsky, P, Rottenfusser, A, DeVries, C, Rudas, M, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, Steger, G G
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3251869/
https://ncbi.nlm.nih.gov/pubmed/22127284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.531
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars